2012-10-04 07:48:09 - Recently published research from Global Markets Direct, "Poxel SA - Product Pipeline Review - 2012", is now available at Fast Market Research

Global Market Direct's pharmaceuticals report, "Poxel SA - Product Pipeline Review - 2012" provides data on the Poxel SA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Poxel SA's corporate website, SEC filings, investor presentations and featured press releases, both from Poxel SA and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468586_poxel_sa_product_pipeline_review_2012 ..


Scope

* Poxel SA - Brief Poxel SA overview including business description, key information and facts, and its locations and subsidiaries.
* Review of

current pipeline of Poxel SA human therapeutic division.
* Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Poxel SA with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Poxel SA's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.

Reasons to buy

* Evaluate Poxel SA's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Poxel SA in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Poxel SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Poxel SA.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Poxel SA and identify potential opportunities in those areas.

Report Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Poxel SA Snapshot
Poxel SA Overview
Key Information
Key Facts
Poxel SA - Research and Development Overview
Key Therapeutic Areas
Poxel SA - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Poxel SA - Pipeline Products Glance
Poxel SA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Poxel SA - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Poxel SA - Drug Profiles
11B-HSD1
Product Description
Mechanism of Action
R&D Progress
AMPK Activator
Product Description
Mechanism of Action
R&D Progress
FXR-Agonist
Product Description
Mechanism of Action
R&D Progress
GLP1 Receptor Agonist
Product Description
Mechanism of Action
R&D Progress
Glucokinase Activator
Product Description
Mechanism of Action
R&D Progress
imeglimin
Product Description
Mechanism of Action
R&D Progress
Imeglimin + Metformin
Product Description
Mechanism of Action
R&D Progress
Poxel SA - Pipeline Products by Route of Administration
Poxel SA - Pipeline Products By Mechanism of Action
Poxel SA - Locations And Subsidiaries
Head Office
Financial Deals Landscape
Poxel SA, Deals Summary
Poxel SA, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Poxel Raises $20 Million In Series A Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Poxel SA, Key Information
Poxel SA, Key Facts
Poxel SA - Pipeline by Indication, 2012
Poxel SA - Pipeline by Stage of Development, 2012
Poxel SA - Monotherapy Products in Pipeline, 2012
Poxel SA - Combination Treatment Modalities in Pipeline, 2012
Poxel SA - Phase II, 2012
Poxel SA - Pre-Clinical, 2012
Poxel SA - Discovery, 2012
Poxel SA - Pipeline By Route of Administration, 2012
Poxel SA - Pipeline Products By Mechanism of Action, 2012
Poxel SA, Deals Summary
Poxel Raises $20 Million In Series A Financing

List of Figures
Poxel SA - Pipeline by Indication, 2012
Poxel SA - Pipeline by Stage of Development, 2012
Poxel SA - Monotherapy Products in Pipeline, 2012
Poxel SA - Combination Treatment Modalities in Pipeline, 2012
Poxel SA - Pipeline Products By Mechanism of Action, 2012

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.